Antibodies

Monoclonal antibody to D-Dimer, clone 3B6


D-Dimer: released by fibrinolysis of FXIII cross-linked fibrin

Order
Quantity
Price
Status
100 µg 365 € available


Documents
Art. No. A046
Background info As the very last step of blood coagulation factor XIII (plasma transglutaminase) cross links D-domains of fibrin molecules. Clot degradation by the fibrinolytic protease plasmin then releases so called D-Dimers.
D-Dimers serve as marker for thrombotic events and the blood disease disseminated intravascular coagulation (DIC). It is an approved diagnostic marker for the exclusion of venous thromboembolism (VTE). There is growing evidence, that D-Dimer antitgen measurements may help clinicians in numerous other clinical scenarios like deep vein thrombosis (DVT), pulmonary embolism, hemolysis or even in chemotherapy (Adam et al., Blood 2009; 113:2878-87)
Host Mouse
Immunogen Human cross-linked D-Dimer
Specificity Specific for clot derived XL-FDPs (Cross-Linked Fibrin Degradation Products). Does not react with either fibrinogen or fibrinogen degradation products.
Appearance Single homogenous batch, 0.2 µM filtered supplied liquid in a 20 mM carbonate buffer, pH 9.2 containing 0.1% sodium azide.
Description >80% pure mouse monoclonal antibody (Isotype IgG3), purified by ammonium sulphate precipitation method.
Application Western blot, ELISA, Collodial Gold Lateral flow, Latex agglutination and Red Blood Cell Agglutination
Recommended as capture antibody with A047 in Sandwich Assays – Gold Conjugate lateral flow tests (detection antibody on nitrocellulose) and ELISA (Tag-HRP antibody)
Working dilutions Optimal dilutions should be determined by the end user- For Western-Blottin: 1 / 5,000 to 1 / 15,000 is a rough guideline
Storage Long term storage: < -60°C, Aliquotation is recommended in order to avoid repeated freeze thaw cycles.
Reference(s) Greenberg et al., Am. J. Clin. Pathol. 1987, 87:94-100
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • CELIACHIA 2020

    07.02.2020 - 08.02.2020
    Milan, Italy

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland